NovoCure Ltd (NVCR) · Sep 9, 2026 · Exec change

NovoCure loses longtime director Timothy Scannell in routine board departure

Director retirement — Seat vacated effective September 2, 2026

NovoCure director Timothy Scannell has retired after five years, with no disagreement cited. The filing offers little strategic or financial signal.

The filing discloses a completed board departure, not an operating update. Timothy Scannell retired from NovoCure’s board, and his seat was formally vacated effective September 2, 2026 (Item 5.02). 〔0〕

The stated circumstances make this largely routine. NovoCure says Scannell’s retirement followed five years of service and did not result from disagreement with the company or management (Item 5.02). 〔1〕 With no replacement, strategic shift, or governance dispute disclosed, there is no clean beat-or-miss benchmark and little evidence that the filing changes the investment picture.

Original filing on SEC EDGAR

More NovoCure Ltd news

NovoCure loses longtime director Timothy Scannell in routine board departure | NVCR Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.